Abstract | Advances in understanding the biology of tumour progression and metastasis have clearly highlighted the importance of aberrant tumour metabolism, which supports not only the energy requirements but also the enormous biosynthetic needs of tumour cells. Such metabolic alterations modulate glucose, amino acid and fatty-acid-dependent metabolite biosynthesis and energy production. Although much progress has been made in understanding the somatic mutations and expression genomics behind these alterations, the regulation of these processes by microRNAs (miRNAs) is only just beginning to be appreciated. This Review focuses on the miRNAs that are potential regulators of the expression of genes whose protein products either directly regulate metabolic machinery or serve as master regulators, indirectly modulating the expression of metabolic enzymes. We focus particularly on miRNAs in pancreatic cancer.
Introduction
Pancreatic cancer is the fourth leading cause of cancerrelated deaths, with a 5-year survival rate of 6%. 1 An extremely aggressive tumour growth rate and a high incidence of metastasis are characteristic of pancreatic cancer. The poor prognosis of this malignancy reflects late diagnosis and poor response to the current standard of care (gemcitabine). Thus, to devise better diagnostics and therapeutics for pancreatic cancer, an urgent need exists to understand the biology of the disease at a molecular level. As with most other cancers derived from epithelial cells, pancreatic cancer initiation and progression involves multiple signalling networks that alter the balance from controlled cell growth to uncontrolled proliferation and metastatic potential.
From a metabolic standpoint, most of these signalling networks act to alter the energy profile of cancer cells and enhance the production of biosynthetic intermediates, which are required for generating the building blocks to sustain growth and survival in unfavourable microenvironments. Aberrant expression and activity of metabolic enzymes is one of the hallmarks of cancer. These metabolic alterations are only just beginning to be understood in pancreatic cancer, and have vast implications for diagnosis and therapy. Alterations in the expression of glucose transporters (for example, GLUT-1) have been linked with disease prognosis and staging. 2 Polymorphisms or mutations in genes involved in glucose metabolism are also important predictors of overall survival of patients with pancreatic cancer. 3 Several key pathways, including Kras, hypoxia-inducible factor 1-� (��F1�), p53 and mammalian target of rapa-� (��F1�), p53 and mammalian target of rapa-(��F1�), p53 and mammalian target of rapamycin (mTOR), that regulate the expression and activities of metabolic enzymes are altered in pancreatic cancer. 4-6 18 F-labelled fluorodeoxyglucose (FDG)-based PET is successfully being used to diagnose the presence and size of pancreatic tumours, indicating that increased glucose uptake and metabolism is a prominent feature in pancreatic cancer. 7, 8 miRNAs are noncoding RNAs that are 18-25 nucleotides long. They regulate gene expression via complementarity with the 3'-untranslated region (3'-UTR) of their target mRNAs. miRNAs regulate gene expression either by target mRNA degradation, repression of its translation or sometimes by upregulation of the target gene. The expression of the vast majority of oncogenes and tumour suppressors is fine-tuned by miRNAs in response to a variety of extracellular cues. [9] [10] [11] Evidence indicates that cancers of multiple origins owe their pathogenesis to altered miRNA regulation.
12,13 miRNAs directly or indirectly regulate several key enzymes and/or signalling hubs that cause alterations in metabolic pathways, resulting in tumour progression and/or meta stasis. The field of miRNA-mediated metabolic regulation is only beginning to unfold and is opening new dimensions for cancer researchers. �n this Review we present a comprehensive summary of miRNA-mediated metabolic regulation in cancer, with a special emphasis on pancreatic cancer ( Figure 1 ; Table 1 ).
Metabolic activity regulating miRNAs
As evident from a plethora of studies, miRNAs regulate a number of physiological processes, including haematopoiesis, stem cell differentiation, adipocyte differentiation and insulin secretion. 12, 13 Furthermore, involvement of miRNAs in cancer, diabetes and other metabolic diseases has been described extensively. 12 �t is important to note that the regulation of metabolism by miRNAs is not a one-way road; metabolic alterations in the extracellular milieu also tend to regulate miRNA expression and activity. Cellular stimuli as diverse as oxidative stress, glucose levels and hypoxia critically orchestrate miRNA activity evidence for the role of oxidative stress in controlling miRNA expression came from Simone et al., 14 who identified induction of miRNA expression in human fibroblasts by ionization-mediated oxidative stress. Similarly, ROS-producing agents such as tert-Butyl hydroperoxide increase the transcription of multiple miRNAs and lead to a corresponding reduction in their mRNA targets in auditory cells. 15 ROS-responsive miR-155 and miR-7b Abbreviations: AcCoA, acetyl coenzyme A; �-KG, �-ketoglutarate; AMPK, 5' adenosine monophosphateactivated protein kinase; eIF4E, eukaryotic translation initiation factor 4E; ETC, electron transport chain; FA, fatty acid; glucose-6-P, glucose-6-phosphate; GLUT, glucose transporter; LKB1, liver kinase B1 or serine threonine kinase 11; mTORC1, mammalian target of rapamycin complex 1; PI3K, phosphoinositide 3 kinase; PPP, pentose phosphate pathway; PTEN, phosphatase and tensin homolog; RTK, receptor tyrosine kinase; TCA, tricarboxylic acid.
are upregulated, whereas ROS-responsive miR-7c and miR-99a are downregulated in pancreatic cancer cell lines in contrast to their normal counterparts. 22 Hypoxia �n association with oxidative stress, hypoxia (low oxygen tension) is a common feature of pancreatic tumours. Although low oxygen tension is assumed to kill normal cells, paradoxically, it promotes proliferation and survival of tumour cells. Evidence suggests that hypoxic conditions stimulate a number of transcription factors, such as ��F1�, NF-κB and p53, that modulate tumour metabolism and enable tumour growth under harsh conditions. 23 �ypoxic conditions also cause the upregulation of multiple miRNAs, including miR-21, 23a, 23b, 24, 26a, 26b, 27a, 30b, 93, 103, 103, 106a, 107, 125b, 181a, 181b, 181c, 192, 195 , 210 and 213. 16, 24 �t is notable that miR-210, miR-181b, miR-23a and miR-23b are markers for pancreatic cancer as well. 25, 26 �nterestingly, many of these miRNAs are involved in translating the metabolic effects that are signalled by ��F1�, c-Myc and NF-κB in tumour cells. ��F1�-induced miR-210, which alters oxidative phosphorylation by targeting key components of the electron transport system, is a potential plasma biomarker for pancreatic cancer. 27, 28 Furthermore, hypoxic conditions can also cause the downregulation of certain miRNAs. 24 Overexpression of miR-20a is implicated in a reduction in cellular proliferation and invasiveness of pancreatic cell lines. 29 
Glucose status
As with hypoxic conditions, glucose status also modulates miRNA levels in tumours. �yperglycaemia is an important hallmark of pancreatic cancer, and it is due to hyperglycaemia that patients with diabetes are more prone to developing pancreatic cancer. 30 �n pancreatic cancer, hyperglycaemia is associated with increased invasiveness and motility of cancer cells. 30 The pancreatic islets of hyperglycaemic GK (Goto-Kakizaki) rats, a genetic model of type 2 diabetes, demonstrate marked upregulation of miR-124, miR-212, miR-132 and miR-409-3p in contrast to islets from normal GK mice. 31 Similarly, treatment of the pancreatic cell line M�N6 with high levels of glucose leads to upregulation of miR-30d, which causes insulin gene regulation in pancreatic β cells. 32 
Regulation of metabolic activity by miRNAs
Regulation of glucose uptake by miRNAs Glucose transporters (GLUTs) are ubiquitous membrane proteins that facilitate sugar (glucose, fructose, galactose and xylose) uptake to meet the energy demands of growing and dividing cells. To date, 14 isoforms of GLUTs have been identified, of which GLUT-1-GLUT-4 are well characterized. 33 �n pancreatic carcinoma, GLUT-1 levels are known to be increased compared with GLUT-2 and GLUT-4 levels. 34 Moreover, enhanced expression of GLUT-1 in these carcinomas drives invasion capacity (through induction of matrix metallo proteinase 2 [MMP2]). 35 Owing to the potential effect of GLUT levels on tumour development and metastasis, signalling mechanisms underlying their expression have been investigated. Regulation of GLUT receptor expression by hormones such as insulin, oestrogen, testosterone, glucocorticoids and thyroid hormones, is widely accepted. [36] [37] [38] [39] Reports also suggest that in most tumours, GLUT expression is under the influence of Ras, Src and c-Myc oncogenes. 40, 41 �n addition, hypoxic and ischaemic conditions, which are hallmarks of the tumour microenvironment, drive GLUT expression, [42] [43] [44] and metabolic-stress-induced signalling pathways, such as AMPK, trigger upregulation of GLUT receptors. 45 Given the role of miRNAs in regulating oncogene expression and their expression under hypoxic and/or ischaemic conditions in tumours, their link with GLUT expression is not surprising.
A study in renal cell carcinoma demonstrated that miR-199a, miR-138, miR-150 and miR-532-5p downregulate GLUT-1 expression, whereas miR-130b, miR-19a/b and miR-301a increase GLUT-1 expression. 46 Another group, while studying the role of miRNAs in type 2 diabetes, showed that miR-150 downregulates GLUT-4 levels in rat and human peripheral blood. 47 Notably, miRNAs such as miR-301 and miR-130b are highly expressed in pancreatic tumours, and their role in regulating GLUT-1 expression might explain the increased glucose uptake that is observed in pancreatic adenocarcinoma. 25, 48 Similarly, reduced levels of miR-150, a negative regulator of GLUT-4 expression, have been reported in pancreatic cancer cells. 49 Such alterations in the levels of miRNAs regulating GLUT-1 reflect a mechanism through which pancreatic tumours bypass regulatory checkpoints in GLUT-1 expression to suffice for the energy demands of rapidly dividing cells. Direct regulation of glycolysis by miRNAs miRNAs provide switches for the regulation of glycolysis, turning on and off in response to tumour needs. Studies show that miRNAs not only regulate the irreversible steps in glycolysis, but also other important intermediates of the pathway. For example, miR-122 and the miR-15a/16-1 cluster modulate glycolysis at steps other than the irreversible ones; 50,51 miR-122 targets ALDOA, whereas the miR-15a/16-1 cluster reduces the levels of ALDOA and TP�1 (key enzymes in the glyco lytic pathway).
52,53 miR-122 is under the control of ��F1�, and its loss correlates with increased invasive and migratory properties of tumour cells in hepato cellular carcinoma. 50, 54 Similarly, the miR-15a/16-1 cluster is known for its tumour suppressor activity both in vitro and in vivo. 52 Thus, reduced levels of miR-122 and miR-15a/16-1 might explain the high rates of glycolysis in tumour cells. miR-15a demonstrates cancer-suppressive functions in pancreatic cancer as well; pancreatic cells that over express miR-15a demonstrate reduced viability compared with their normal counterparts. 55 
Indirect regulation of glycolysis by miRNAs
Regulation of growth factor signalling Receptor tyrosine kinases (RTKs), such as epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR), and their corresponding ligands are expressed in a variety of tumours (including pancreatic cancer) and are implicated in cancer progression. 56, 57 Upon activation, RTKs regulate an array of signalling complexes, including ERK, P�3K/ Akt, MAPK and phospholipase C; aberrant expression of RTKs can thus lead to the transformation, survival and growth of tumour cells. 58, 59 Aberrant expression or activation of RTKs is also linked with stabilization of ��F1�, activation of the mTOR pathway, which upregulates aerobic glycolysis, and regulation of PKM2 activity (another key glycolytic enzyme). 60, 61 Cross-regulation of miR-146a and EGFR signalling has been suggested in pancreatic cancer. 62 miR-146a is expressed at low levels in pancreatic cancer and its upregulation diminishes cancer metastasis, partly by down regulating EGFR. �n addition to regulating RTKs, miRNAs also regulate ligands; for example, in head and neck squamous cell carcinoma, an inverse relationship between heparin-binding EGF-like growth factor (�B-EGF) and miR-212 has been reported. 63 �n these cells, reduced levels of miR-212 favour �B-EGF-derived cetuximab resistance. Similarly, in mast cells �B-EGF levels are regulated by miR-132. 64 Both miR-212 and miR-132 are overexpressed in pancreatic cancer, in which �B-EGF might have a role in early phases of cancer progression. 65, 66 Regulation of p53 p53, one of the most common tumour suppressor genes, guards against genomic insult, hence its description as the guardian angel gene. Besides protecting genomic DNA, p53 also modulates cellular metabolism by regulating glycolysis and oxidative phosphorylation. As evident from many studies, p53 exercises its control by inhibiting the expression of GLUT-1, GLUT-4 and phosphoglyceromutase (PGM; a glycolytic enzyme), or through T�GAR-expression-mediated inactivation of PFK1 (T�GAR is TP53-induced glycolysis and apoptosis regulator protein; it inhibits the glycolytic enzyme PFKFB2). 67 Thus, p53 slows down the rate of glycolysis to facilitate the pentose phosphate pathway that provides nucleotide precursors for the repair of damaged DNA. 68 �n parallel with glycolysis retardation, p53 drives oxidative phosphorylation by upregulating subunit � of cytochrome c oxidase and SCO2. 69, 70 �n addition, p53 is also involved in maintaining mitochondrial DNA stability. 71 Some miRNAs are able to control p53 activity. As observed from microarray studies, p53-regulating miRNAs are highly expressed in tumours and their levels are inversely related to p53 expression. �n a report demonstrating the regulation of p53 by miRNAs, Le et al. 72 identified miR-125b as a negative regulator of p53 in zebra fish. Similar observations were made in human cells. 72 �nterestingly, another isoform of miR-125, miR-125a, targets p53 in kidney cells, where ectopic expression of this miRNA reduces p53 protein levels and rescues the cells from arsenic-induced apoptosis. 73 Both of the isoforms of miR-125 are highly expressed in pancreatic cancer and are involved in tumourigenesis. 26 Apart from the miR-125 family, several other miRNAs regulate the levels of p53 in normal and tumour cells, although they remain to be studied in the context of pancreatic cancer.
Regulation of c-Myc
c-Myc is tightly regulated under normal conditions; however, it is aberrantly expressed in the majority of tumours. According to an estimate, deregulated expression of c-Myc underlies 70,000 cancer-associated deaths per year in the USA. 74 c-Myc is a transcription factor that regulates the expression of genes involved in nucleotide metabolism, DNA replication, and ribosomal and mitochondrial biogenesis. �n addition, substantial experimental data support the crucial role of c-Myc in glutamine metabolism. 75 Moreover, in concert with ��F1�, c-Myc regulates glucose uptake and glycolytic enzyme expression, thus favouring tumour growth in hostile environments. 74 Given the relevance of c-Myc in tumour progression, studies identifying c-Myc regulators have gained momentum in the past few years. This increase in studies has led to the identification of miRNAs as novel regulators of c-Myc activity. For example, a study by Akao et al. 76 demonstrated the regulation of c-Myc levels by miR-let-7a in human colon cancer cells. �n xenograft models, let-7a stably transfected cells reduced c-Myc levels and inhibited tumour growth in mice, thus confirming the tumour suppressor activity of let-7a. 77 miR-34c, another important tumour suppressor miRNA, regulates c-Myc levels by directly binding c-Myc mRNA in the 3'-UTR region. 78 Although miR-34c levels are under the control of p53, overexpression studies in pancreatic cancer cells have indicated that miR-34c exerts tumour suppressor activity even in the absence of p53. 79 Taken together, these reports support the view that miRNAs represent a novel switch for c-Myc activity, which could be useful in generating new therapeutic modalities against tumour growth. 80, 81 Constitutive activation of Ras targets multiple signalling networks, such as Raf/MEK/ERK and P�3K/Akt, to transduce the oncogenic signals and commit the cells to RAS-mediated transformation. 82 Apart from transformation, Kras also regulates cancer metabolism. 83, 84 �ncreasing evidence demonstrates a direct relationship between Kras, mitochondrial dysfunction and ROS production in tumour cells. Kras disrupts mitochondrial function by opening mitochondrial permeability pores, thus inactivating oxidative phosphorylation. 85 �ence, in comparison to normal counterparts, Kras transformed cancer cells exhibit increased glycolysis. Also, Kras promotes tumour growth by decreasing pyruvate flux through the tricarboxylic acid (TCA) cycle and promoting glutamine metabolism. 86 Owing to the universal role of Kras in tumourigenesis, various studies have investigated a possible link between Kras and miRNAs. Johnson et al. 87 were the first to demonstrate a link and showed that Kras is a direct target of let-7 miRNA in lung tumours. A similar association was also observed in the context of pancreatic cancer, in which miR-96 was found to downregulate Kras levels. 88 An inverse correlation between miR-143 and Kras has also been highlighted in colorectal cancer cells and prostate cancer cells. 89, 90 �nterestingly, in pancreatic cancer cells, miR-143 is under the control of Kras, thus suggesting a feedback control provided by miR-143 on Kras levels. 91 �n pancreatic adenocarcinoma, miR-217 slows tumour growth and colony formation by targeting Kras. 92 miR-217, in combination with miR-196a, provides considerable sensitivity to distinguish between healthy tissue, pancreatic ductal adenocarcinoma and chronic pancreatitis in samples from fine needle aspirates. 93 �n addition, reciprocal relations between miR-216b and Kras exist in cells derived from the Kras;Pdx1-Cre;�NK4a/Arf spontaneous model of pancreatic cancer. 94 
Regulation of RAS
RAS mutations are a common driving force for tumourigenesis in cancers of multiple origins. For example, KRAS mutations are present in >90% of pancreatic adenocarcinoma.
Regulation of HIF1α
��F1� is a central mediator of oxygen homeostasis in mammalian systems. �ypoxic conditions are common in pancreatic tumours and the resultant activation of ��F1� critically regulates tumour growth and survival by inducing glycolysis, aerobic respiration and angiogenesis-related factors, thus laying the foundation for aerobic glyco lysis in cancer cells (also known as the Warburg effect). ��F1� controls glycolysis by upregulating the expression of key glycolytic enzymes, including GLUT-1, GLUT-3, �K��, PFK-L, ALD-A, PGK1, ENO-� and PKM2. [95] [96] [97] ��F1� also favours anaerobic respiration by activating pyruvate dehydrogenase kinase 1 (PDK1) and lactacte dehyrogenase A (LD�A) in malignant cells. [95] [96] [97] ��F1� is under the transcriptional control of mTOR as well as various oncogenes and growth factors, such as �Ras, c-Myc, Src, EGF and �GF. 98, 99 miRNAs have also emerged as a new class of regulators that regulate ��F1� levels in tumours. ��F1� is a direct target of the miR-17-92 cluster, which itself is under the control of c-Myc. 100 Such feedback regulation illustrates the complex interplay between c-Myc and ��F1� in tumours. Similarly, ��F1� is also regulated by other miRNAs. miR-199a mediates inhibition of ��F1�, potentially in a feedback manner through Twist-1. 101, 102 miR-20b also abrogates ��F1� levels under hypoxic conditions. 103 Through ��F1�, miR-20b regulates VEGF and angiogenesis in tumours. �n addition, miR-519c, miR-107 and miR-155 also target ��F1� levels in endothelial cells, colon cancer cells and colorectal adenocarcinoma, respectively. [104] [105] [106] These findings could have relevance for pancreatic cancer, as miR-155 and miR-107 are part of the miRNA signature of pancreatic cancer. 25 Furthermore, miR155 is overexpressed in pancreatic intraepithelial neoplasia (Pan�N)-2 and Pan�N-3, in contrast to non-neoplastic ductal epi thelium, suggesting it has a role in early pancreatic cancer pathogenesis. 107, 108 miR-155 levels are also increased in cyst fluid samples obtained from patients with noninvasive intraductal papillary mucinous neoplasm (�PMN), compared with those who have benign pancreatic cysts. 109 Overexpression studies suggest a positive correlation between ��F1� and miR-21 levels. miR-21 is overexpressed in Pan�N-3 lesions, but not Pan�N-2 lesions and hence might have a role in the later stages of pancreatic cancer pathogenesis. 107 Similarly, a role for hypoxia-induced miR-424 in stabilizing ��F1� has been reported. 110 Under normoxic conditions, basal levels of ��F1� are maintained by the ubiquitin ligase system. �owever, demand of ��F1� is high under hypoxia and the degradation process needs to be under control. miR-424, differentially expressed in almost all tumour types, actively participates in slowing the turnover rate of ��F1� by targeting cullin 2 scaffolding protein for ubiquitin ligase system in human endothelial cells. Thus, miR-424 is crucial for ��F1�-derived tumourigenesis.
Regulation of TCA machinery by miRNAs
Cancer cells, like other rapidly proliferating cells, bypass oxidative phosphorylation (the TCA cycle) and rely mostly on nonoxidative pathways (lactate production) to meet their high energy demands. 111 Moreover, this metabolic shift enables cancer cells to produce various building blocks, such as fatty acids, lipids, nucleotides and proteins, while still supplying sufficient energy. �nterestingly, however, oxidative phosphorylation is not completely abolished in cancer cells and still operates at a low level. 112 The preference of cancerous tissue for non-oxidative pathways is regulated through mol ecular switches such as c-Myc and ��F1�. Nevertheless, the role of miRNAs in coordinating these preferences cannot be underestimated. Accumulating evidence indicates that miRNAs directly and indirectly regulate the TCA cycle. The first evidence for direct regulation came from Wilfred et al., 113 who predicted the role of miR-103 and miR-107 in regulating acetyl CoA and lipid levels in cellular systems. miR-210, another key regulator of mitochondrial function, directly represses SD�D, which is an important member of the TCA cycle and electron transport system, in lung adenocarcinoma. 27 Furthermore, miR-210, under the transcriptional control of ��F1�, negatively regulates the mitochondrial TCA cycle by targeting �SCU and COX10, and hence switches the fate of pyruvate toward lactic acid conversion in breast and colon cancer cells. 114 Given the increased levels of miR-210 in pancreatic cancer, it is expected that similar mechanisms might be operational in this cancer. 27 With regard to indirect regulation of the TCA cycle, c-Myc mediates repression of miR-23a/23b to promote oxidative phosphorylation. 115 c-Myc also replenishes glutamine, a TCA cycle substrate, through increased transcription of mitochondrial glutaminase and hence stabilizes mitochondrial metabolism and growth. 115, 116 This mechanism was confirmed by silencing glutaminase in c-Myc transfected cells, which led to reduced cell proliferation. 115 Reciprocally, miRNAs can modulate the flux of glucose through the TCA cycle by regulating c-Myc as described above. Besides c-Myc, p53 also modulates aerobic respiration in cancer cells through the synthesis of cytochrome c oxidase 2 (SCO2); inactivation of the gene that encodes this protein induces aerobic respiratory failure. 117 �nterestingly, many miRNAs, including miR-125b, miR-30 and miR-504, target p53. 72, 118, 119 �ence, these findings immediately suggest the possible control of oxidative phosphorylation through miRNAmediated p53 reduction in various tumours, including pancreatic cancer, in which differential expression of miR-125b has been reported. 120 Directing flux via glycolysis or the TCA cycle After glycolysis, pyruvate can undergo either aerobic or anaerobic respiration, depending on levels of LD�A, monocarboxylate transporters (MCTs) and pyruvate dehydrogenase (PD�). Oncogenes such as NF-κB, c-Myc and Akt directly or indirectly regulate these enzymes and preferentially drive anaerobic respiration in cancer cells. For example, ��F1�, upon oncogenic stimulation, upregulates LDHA transcription with a concomitant increase in the PD� inactivating enzyme PDK1, and thus enables pyruvate to bypass aerobic respiration. [95] [96] [97] 121, 122 Similarly, c-Myc enhances lactate production through LD�A and PDK1 activation. 123 These observations imply that any factor promoting ��F1� and c-Myc will indirectly favour lactic acid generation.
As miRNAs are critical regulators of ��F1� and c-Myc expression, they have a role in regulating the flux of glucose through either aerobic or anaerobic respiration. miR-103/107, which is critical for pancreatic tumourigenesis, 124 has been shown to regulate PDK4, a critical inactivator of pyruvate dehydrogenase enzymatic activity. 113 The 3'-UTR of PDK4 transcript is predicted to carry a miR-103/107 recognition sequence(s). 113 LDHA is a direct target of miR-503-3p. 125, 126 The role of miR-375 in targeting lactate dehydrogenase B (LD�B) has also been highlighted. 127 LD�B, which has the opposite function to LD�A (in that it converts lactate into pyruvate), might help glucose-deprived tumour or stromal cells utilize the lactate secreted by other tumour cells. �n addition, a report by Zha et al. 126 suggests that LD�B is a crucial factor in mTOR-mediated tumourigenesis. These findings might be important in the context of pancreatic neuro endocrine tumours as miR-375 is highly expressed in pancreatic β cells. The secretion of lactate outside the cell is directly regulated by miR-29a, miR-29b and miR-124, which target the 3'-UTR of MCT1 in pancreatic β cells. 128 
Regulation of glutamine metabolism
Research suggests that glutamine is another indispensable molecule for tumour growth and expansion. Although many amino acids might serve as a nitrogen source, tumour cells preferentially consume glutamine at a faster rate than any other amino acid. 129 �igh levels of glutaminase and organic phosphorus, a cofactor for glutaminase activity, are linked with tumour cell proliferation. 130 Glutaminase-mediated deamination results in the conversion of glutamine to glutamate, which further undergoes enzymatic conversion to form �-ketoglutarate, an important substrate for the TCA cycle. 131 Thus, the apparent metabolic function for glutamine uptake is to sustain the TCA cycle in tumour cells, albeit at a low level. �n addition to regulation by multiple factors in the tumour microenvironment, including oxygen deprivation, glutaminolysis is also regulated by miRNAs. Glutaminase is a direct target of miR-23a/b, and c-Mycmediated reduction of these miRNAs rescues the enzyme and promotes glutaminolysis. 115 As with most tumours, a crucial role of c-Myc in pancreatic tumourigenesis is well established. �owever, the exact role of miR-23a/b in pancreatic cancer remains to be explored. p53, a direct target of miR-125b, miR-30 and miR-504, also has a crucial role in maintaining glutamine levels through the activation of glutaminase 2 (GLS2), another important glutamine metabolizing enzyme. 72, 118, 119 As well as glutamine breakdown, direct effects of miRNAs on glutamine synthesis are evident. miR-29a, whose overexpression diminishes proliferation and invasiveness in pancreatic cancer cell lines, regulates glutamine levels in intestinal bowel disease by directly targeting glutamine synthetase and thus causing increased intestinal permeability in this disease. 132, 133 Similar mechanisms might also exist in pancreatic cancer, in which miR-29a overexpression might provide glutamine as an alternative energy source.
Regulation of fatty acid metabolism Altered lipid metabolism, although less well recognized, is also an important factor in many tumours. �n tumours, the P�3K/Akt pathway is centrally involved in fatty acid biogenesis through the activation of ATP citrate lyase and inhibition of fatty acid β-oxidation enzyme CPT1A. 134, 135 Given the important role of P�3K/Akt in the regulation REVIEWS of lipid metabolism in tumours, it is likely that miRNAs regulate lipid metabolism in tumours via this pathway. miR-21, which inhibits the P�3K/Akt pathway negative regulator PTEN, is induced in gemcitabine-resistant pancreatic cancer cells and is downregulated by curcumin or its analogue CDF. 136 Although not much is known about miRNA-mediated direct regulation of fatty acid metabolism in pancreatic cancer, fatty acid metabolism is crucial for pancreatic cancer initiation and progression. A highfat diet that triggers inflammation in Kras animal models of pancreatic cancer aggravates tumour promotion. 137 This tumour promotion is caused by dramatic changes in energy metabolism through enhancement of pancreatic exocrine insufficiency, metabolic rates and expression of genes involved in mitochondrial fatty acid β-oxidation. 137 Obesity and a high-fat diet are directly linked with the incidence of human pancreatic cancer.
138-140
The tumour microenvironment and miRNAs
The tumour microenvironment (often termed the stroma) is central to tumour growth and progression. The importance of the environment can be understood by the fact that most cells surrounding a tumour show abnormal behaviour and genetic instability. Cancer cells grown in the vicinity of fibroblasts have increased mitochondrial mass; on the other hand, the fibroblasts in such co-cultures demonstrate a dramatic loss of mitochondria. 141 This observation indicates the parasitic role of tumours in drawing essential nutrients from the surrounding environment. Given the critical role of the stroma in maintaining the aggressive behaviour of a tumour, a multitude of studies are focusing on controlling tumour growth through stromal alteration. �n this regard, miRNAs associated with stromal components might prove to be a valuable therapeutic target.
To date, a number of miRNAs have been evaluated for their effects on stromal cellular and noncellular components. For cancer-associated fibroblasts, various studies have reported an upregulation of miR-16, miR-320, miR-504, miR-424 (a cluster of miRNAs found on chromo somal location Xq26.3), miR-29b and miR-146a. 142, 143 Although the roles of miR-16 and miR-320 are still not clear, the other miRNAs were shown to regulate cancer-associated fibroblast genes. Of note, miR-504 and miR-424 also have a crucial role in cancer metabolism through the activation of ��F1� and suppression of p53 in tumour cells. 110, 144 Levels of miR-31, which is associated with oxidative stress and activation of the hypoxic response, are also reduced in cancer-associated fibroblasts. 145 A key miRNA that is readily detectable in the plasma of patients with pancreatic cancer is miR-10b. 146 Expression of this miRNA is increased in cancer cells compared with CK19-positive epithelial cells in benign lesions from endoscopic ultrasonography-guided fine-needle aspirate (EUS-FNA) samples. 146 Although miR-10b does not directly target metabolic genes, it regulates the expression of �oxD10, which in turn can regulate angiogenesis and expression of MMP14 and uPAR, which cause remodelling of the pancreatic tumour microenvironment. 147, 148 Thus, it seems that by modulating the tumour microenvironment, miR-10b can alter the tumour-stromal metabolic interactions in pancreatic adenocarcinoma.
Can miRNAs differentiate pancreatic disease?
Given the crucial role of miRNAs in coordinating vast metabolic processes, many studies have investigated the possible links between miRNA expression and cancer progression. With regard to pancreatic cancer, an avalanche of microarray data has produced a long list of differentially expressed miRNAs. Bloomston et al. 26 compared the miRNA profile of pancreatic cancer, chronic pancreatitis (an inflammatory state of the pancreas, which is associated with an increased risk of pancreatic cancer 149 ) and normal pancreas. According to their findings, a total of 30 miRNAs were upregulated and three miRNAs were downregulated in pancreatic cancer compared with normal pancreas; chronic pancreatitis demonstrated an overexpression of 22 miRNAs and suppression of two miRNAs compared with normal pancreas. �n comparison with chronic pancreatitis, 15 miRNAs were upregulated and eight miRNAs were downregulated in pancreatic cancer. Corroborating these studies, Lee et al. 25 also investigated the miRNA expression profile of pancreatic cancer by assessing 200 miRNAs in clinical samples of pancreatic cancer. Similarly, Ali et al. 150 identified differentially expressed miRNAs in the plasma of patients with pancreatic cancer versus healthy volunteers. miRNA status has also been extensively investigated in 21 human pancreatic adenocarcinoma cell lines compared with normal counterparts. 22 �mportantly, these studies identified a group of miRNAs that seem to underlie or drive the pathophysiology of chronic pancreatitis and/or pancreatic cancer. Moreover, the comparison between chronic pancreatitis and pancreatic cancer pinned down the key miRNAs associated with the altered metabolic states of the respective diseases. For example, in the study by Bloomston et al., 26 of the 30 overexpressed miRNAs in pancreatic cancer, 12 miRNAs are hypoxamir (miRNA associated with hypoxia), which is in line with the low oxygen environment of pancreatic tumours; in chronic pancreatitis, which is more of an inflammatory state, only two of the 22 miRNAs are hypoxia responsive. Similarly, in contrast to chronic pancreatitis, pancreatic tumours demonstrate an increased expression of glucose responsive miRNAs, such as miR-221 and miR-21. Chronic pancreatitis causes altered expression of a number of ROS-associated miRNAs compared with pancreatic tumour samples; four of 22 miRNAs in chronic pancreatitis are ROS responsive (according to other studies; miR-339, miR-128b, miR-125b-1/2). 151, 152 �owever, in pancreatic tumours only miR-125a is ROS responsive.
miRNAs as biomarkers for pancreatic disease
Given that miRNAs are markers of the metabolic state, they can be used as a potent tool to monitor cancer progression and the effectiveness of cancer therapeutics. Sensitivity to chemotherapy is governed by the metabolic state of the tumour. 18 F-FDG-PET imaging, which measures glucose uptake and metabolism in tumours, is being successfully used for cancer staging and for assessing tumour response to therapy in pancreatic cancer. 153 Furthermore, direct inhibitors of glycolysis have demonstrated marked inhibition of growth in pancreatic cancer cells under cell culture conditions. 154 miR-214, which is downregulated in pancreatic cancer and determines sensitivity of pancreatic cancer cells to gemcitabine, targets PTEN in ovarian cancer and might induce mTOR-mediated activation of aerobic glycolysis in pancreatic cancer. 55, 155 miR-210, a ��F1�-inducible miRNA is upregulated in the plasma of patients with pancreatic cancer. 156, 157 This miRNA targets the enzyme glycerol-3-phosphate dehydrogenase 1-like (GAPD1L), inhibits P�D activity and stabilizes ��F1� in a positive feedback fashion. 158 Plasma levels of miR-21, which downregulates PTEN, are increased in patients with pancreatic cancer compared with healthy controls. 150 Expression of miR-21 is high in chemoresistant cell line models of pancreatic cancer and is correlated with worse prognosis in pancreatic cancer. 150 �n contrast to levels of miR-21, levels of miR-320 family members, which downregulate insulin-like growth factor 1 (�GF-1), are substantially reduced in plasma from patients with pancreatic cancer compared with healthy controls. 150 The upregulation of miR-21 and downregulation of miR-320s indicates the RTK-mediated activation of mTOR signalling. Another miRNA that is overexpressed in the plasma of patients with pancreatic cancer and serves as a potential biomarker for disease prognosis and a biomarker for early pancreatic neoplasia is miR-155. 107, 109, 146, 159, 160 miR-155 levels might determine gemcitabine sensitivity in patients with pancreatic cancer by regulating the levels of cytidine deaminase. 161, 162 Conclusions Cancer metabolism and the role of miRNAs are rapidly growing research fields, which could soon unfold the secrets to check cancer-associated mortality. �ere, we have summarized findings pertaining to metabolic reprogramming by miRNAs in pancreatic cancer. Current knowledge suggests that in response to various oncogenic or microenvironment signals, miRNAs regulate cellular metabolism to facilitate tumour growth, metastasis and survival of tumour cells under harsh conditions. Although this Review has provided a thorough insight into miRNA responsive and inducible factors, and the regulated molecular pathways, further studies are warranted regarding their biogenesis in the context of metabolic states of the tumour cells. �t is essential to understand the key metabolic switches favouring the expression of a particular set of miRNAs. Similarly, an understanding of potential inactivating mutations in the 3'-UTR of the miRNA target mRNAs will be of clinical significance. Furthermore, how the miRNA machinery regulates the overall metabolic state of the tumour, including the stroma, so as to facilitate progression of this lethal disease, remains to be answered.
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